Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000016000
Abstract: Abstract Rationale: Mixed adenoneuroendocrine carcinoma (MANEC) is a rare neoplasm, and consensus on the treatment is unavailable. Patient concern: A 60-year-old Chinese man presented with obstructive symptoms while eating and paroxysmal stomach pain for more… read more here.
Keywords: chemotherapy; mixed adenoneuroendocrine; adjuvant chemotherapy; xelox adjuvant ... See more keywords
Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study
Sign Up to like & getrecommendations! Published in 2020 at "Asia-Pacific Journal of Clinical Oncology"
DOI: 10.1111/ajco.13321
Abstract: Capecitabine plus oxaliplatin (XELOX) as adjuvant therapy for gastric cancer (GC) reduces cancer recurrence and improves survival. S‐1 plus oxaliplatin (SOX) is well‐tolerated and effective against advanced GC, and also be used widely in adjuvant… read more here.
Keywords: oxaliplatin xelox; plus oxaliplatin; capecitabine plus; cancer ... See more keywords